Resources
32 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 4/21/2021 (updated 4/5/2024)
This News Brief describes the need for harm reduction and treatment services in rural areas for people who use psychostimulants and how those services can be provided by the opioid treatment program
Posted 3/25/2021 (updated 4/5/2024)
Integrating Health Promotion for People Who Inject Drugs (PWID) Into Opioid Use Disorder (OUD) Services
The workshop will present strategies to integrate HIV, hepatitis, and sexual health concerns into services for PWID. The session will focus on communication skills, assessment techniques, and building motivation among PWID to make healthier choices. The presenter will look at programmatic and clinical-level integration strategies and offer participants an opportunity to assess current service delivery models and develop a plan to enhance care.
Posted 3/10/2021 (updated 4/5/2024)
There are safe ways to dispose of syringes you find on the ground. Sharing injection drug equipment can transmit infections, but there is little risk to someone who is accidentally poked or scratched by a discarded syringe.
Below you'll find information on how to pick them up, where to drop them off, and ways to get involved in cleaning up your neighborhood.
Posted 1/27/2021 (updated 4/4/2024)
The current study examined the accuracy of sensory discernment strategies by measuring study participants’ descriptions of the last opioid injected and checked with a fentanyl test strip (FTS) by that test's positive/negative result. The primary objective was to determine associations between FTS results and descriptions of the illi it opioid's physical appearance and physiological effects.
Posted 1/20/2021 (updated 4/4/2024)
People who use drugs (PWUD) in the U.S. experience disproportionate adverse health outcomes and mortality as compared with the population as a whole (Lake & Kennedy, 2016; Reisinger, Pratt, Shoenborn, & Druss, 2017). Similar health outcomes have been reported elsewhere, for example in the UK (Neale, 2004), and across 8 other European countries (Bargagli et al., 2006). In the U.S. health outcomes among PWUD are intensified by the overdose pandemic, epidemic rates of HIV, hepatitis A and C, skin and soft tissue infections (CDC Centers for Disease Control and Prevention, 2020; Hagen, Thiede, & Des Jarlais, 2005; Scholl, Seth, Kariisa, Wilson, & Baldwin, 2019), and by structural barriers thwarting health access and utilization.
Posted 12/23/2020 (updated 4/4/2024)
This technical package provides evidence of the effectiveness of strategies and approaches for supporting successful planning, design, implementation, and sustainability of syringe services programs (SSPs). It provides a broad framework for new and existing SSPs to ensure needs-based service delivery, reduce harms related to injection drug use, and link participants to services that support their health and wellness.
Posted 10/14/2021 (updated 4/3/2024)
The workshop presented strategies to integrate HIV, hepatitis, and sexual health concerns into services for PWID. The session will focus on communication skills, assessment techniques, and building motivation among PWID to make healthier choices. Mr. Sacco looked at programmatic and clinical-level integration strategies and offered participants an opportunity to assess current service delivery models and develop a plan to enhance care. Mrs. Bell and Ms. Chavis intrdoduce participants to resources and funding opportunities available through HRSA’s HIV/AIDS Bureau (HAB).
Posted 12/15/2020 (updated 4/3/2024)
This workshop presented strategies to integrate HIV, hepatitis, and sexual health concerns into services for PWID. The session focused on communication skills, assessment techniques, and building motivation to make healthier choices. The presentation looked at programmatic and clinical level integration strategies and offered participants a chance to assess current service delivery models and develop a plan to enhance care.
Posted 8/19/2021 (updated 4/2/2024)
In spring 2021, pharmaceutical manufacturers and distributors notified syringe services programs (SSPs) and partners that there would be significant interruptions in the supply of injectable/intramuscular (IM) naloxone. Currently, production and distribution delays are expected to last until fall 2021. This will specifically affect SSPs because IM naloxone is the most affordable formulation, and therefore is most commonly utilized by programs that distribute large volumes of naloxone to reduce fatal overdose rates.